Cardax launches first product ZanthoSyn™

[USA] Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that it has launched its first commercial product, ZanthoSyn, a safe anti-inflammatory for general health.

ZanthoSyn is a novel astaxanthin dietary supplement with superior absorption and purity, and is available through Cardax’s commercial website,www.zanthosyn.com.

Astaxanthin is a clinically studied ingredient with safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health.* The form of astaxanthin utilized in ZanthoSyn has demonstrated excellent safety in peer-reviewed published studies and is designated as GRAS (Generally Recognized as Safe) according to FDA regulations.

Superior Absorption. In a head-to-head human study against a leading microalgal astaxanthin dietary supplement, ZanthoSyn provided 2.85 times more absorption (p = 0.013)—defined as the total amount of astaxanthin measured in the bloodstream over a 24-hour period following a single 24 mg dose. This means that two 12 mg capsules of ZanthoSyn deliver nearly the same amount of astaxanthin to the blood stream as six 12 mg capsules of microalgal astaxanthin. This study was sponsored by Cardax and led by Dr. Jon L. Ruckle, Cardax’s lead medical advisor since 2013. Dr. Ruckle was the former Medical Director of the Covance Clinical Research Unit in Honolulu and has been a principal investigator of more than 350 clinical trials.

“These results demonstrate a highly significant and clinically meaningful advantage for ZanthoSyn,” concluded Dr. Ruckle. “We were also pleased to see very consistent subject-to-subject absorption profiles.”

Purity. ZanthoSyn contains pure astaxanthin prepared by natural product total synthesis. In contrast, the astaxanthin extracted from microalgae is obtained in a complex mixture, which may include many unknown microalgal by-products. The precision of synthetic manufacturing also provides healthcare professionals and health-conscious consumers with confidence in the quality and consistency of dosing from every capsule. ZanthoSyn is manufactured in accordance with current Good Manufacturing Practice (cGMP) regulations for dietary supplements.

“We are very pleased to launch this exciting product,” said David G. Watumull, President and CEO of Cardax. “Our team includes leading astaxanthin experts and is uniquely positioned to lead the roll-out of our commercialization strategy over the next several quarters.”

“Based on astaxanthin’s published safety and efficacy data together with the superior absorption and purity of ZanthoSyn, I strongly recommend ZanthoSyn to those seeking a safe anti-inflammatory for their general health needs,” added Dr. Jon L. Ruckle.

 

View original article at: Cardax launches first product ZanthoSyn™

Algae World News post end logo

 

 

 

 

[interaction id=”578e20eb33e3688a29de3477″]

 

Leave a Reply